Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007. Specific management expertise includes the development, approval and commercialisation of oncology medicines. We are developing a portfolio of first-in-class and best-in-class pharmaceutical products designed to treat life-threatening or debilitating diseases. Our primary focus is in the area of oncology, although our technology platform has broader clinical potential.

OBI Pharma, Inc. engages in the development and licensing of novel therapeutic agents for unmet medical needs against cancer. Its products include Adagloxad Simolenin, which is a late-stage novel active immune-oncology Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The company was founded by Michael N. Chang on April 29, 2002 and is headquartered in Taipei, Taiwan.

Selvita SA engages in the discovery, regulatory studies, as well as research and development. It operates through the following segments: Services Executed in Poland, Bioinformatics, Services Executed in Croatia, Subsidies, and Other. The company was founded by Boguslaw Sieczkowski in September 2007 and is headquartered in Krakow, Poland.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Zhejiang Bozhen Biotechnology Co., Ltd., established on 2015-06-08, Business scope includes general items:Research and development of bio-based materials technology;Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Wholesale medical masks;daily mask(non-medical)Production;daily mask(non-medical)Sales;Wholesale of protective equipment for medical staff;Production of Class I Medical Devices;Import and export;Technology Import and Export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Production of medical masks;Production of protective equipment for medical personnel(Class II medical device);Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).(The branch office is located in:Weishiqi Road, Yueqing Economic Development Zone, Yueqing City261NoCbuilding403room)

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Orca Bio is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients. Orca Bio has developed a pipeline of proprietary technologies that have the potential to impact over 100 malignant and auto-immune diseases. Orca has assembled a team of world-leading experts and technologists to execute this vision.

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxonin for bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Ohara Pharmaceutical Co., Ltd. manufactures, distributes, imports, and exports pharmaceuticals and related food additives. It also specializes in orphan drugs for Leukemia, Leukocytpenia, stem cell transplantation, and Parkinson's disease. The company was founded on November 5, 1964 and is headquartered in Koka, Japan.

Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies. Oryzon Genomics has a growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.

Sichuan Xingkerong Pharmaceutical Co., Ltd., established on 2011-04-01, Business scope includes new drug research and development;wholesale:biochemical drug,Chinese Herbal Medicine,Chinese herbal medicine(Except for precious Chinese herbal medicines),Biological product(Free of prophylactic biologicals),Chemical API,Antibiotic API,Chinese patent medicine,Chemicals,antibiotic preparation,Health products(Except pre-approval),Class I medical device,Agricultural and sideline products(Does not contain grain,cotton,Oil,raw silk,Silkworm cocoons);Biotechnology product technology development,technical consulting,Technology Transfer and Technical Services;Engaged in foreign trade operations of goods technology and agent import and export;Drug logistics and distribution;Investment Advisory(Do not engage in illegal fundraising,Financial activities such as absorbing public funds).(The above business scope does not include items restricted or prohibited by national laws and regulations,Except those involving the implementation of special access management measures stipulated by the state,Those involving licenses can only carry out business activities with the relevant licenses).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Except those involving the implementation of special management measures stipulated by the state)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical to clinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization.